Home › Companies › ACLARIS THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ACLARIS THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2024: 4 items on ACLARIS THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 2 approved · 2 passed (calculated).
Significant dissent: 1 director (35.6% against).
Notable dissent: 1 other board item (35.9% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 8.0%, as of September 30, 2026) · BML Capital (13F, 6.9%, as of September 30, 2026)
Explore ACLARIS THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ACLARIS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Christopher Molineaux | 29,165,764 | -- | -- | 16,154,877 | 12,468,248 | 64% | Passed (calculated) | — |
| Elect Director: Vincent Milano | 42,267,754 | -- | -- | 3,052,887 | 12,468,248 | 93% | Passed (calculated) | — |
| 2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement | 29,025,583 | 16,273,816 | 21,242 | -- | 12,468,248 | 64% | Approved | — |
| 3. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024 | 56,610,643 | 1,154,624 | 23,622 | -- | -- | 98% | Approved | — |
Source: ACLARIS THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
106 asset managers disclosed a vote on at least one ACLARIS THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Christopher Molineaux
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Christopher Molineaux”): 29,165,764 for, 16,154,877 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 7,104,668 for, 3,788,377 withheld, 38,352 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,882,172 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 2,706,426 | Withhold |
| Fidelity | 2,114,216 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 419,704 | Withhold |
| Equitable | 0 | 0 | 0 | 186,273 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 115,378 | Withhold |
| TIAA | 0 | 0 | 0 | 97,857 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 57,200 | Withhold |
| Pacific Life | 25,112 | 0 | 0 | 22,969 | Mixed |
| T. Rowe Price | 47,442 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 34,229 | Withhold |
| Harbor ETF Trust | 30,304 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 24,620 | Withhold |
| Nationwide | 0 | 0 | 0 | 21,071 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 16,300 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 16,142 | Withhold |
| ProShares | 0 | 0 | 0 | 15,939 | Withhold |
| SEI | 0 | 0 | 0 | 15,900 | Withhold |
| John Hancock | 0 | 0 | 14,788 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 12,653 | 0 | Abstain |
| DWS | 0 | 0 | 0 | 10,759 | Withhold |
| Jackson National | 0 | 0 | 8,881 | 0 | Abstain |
| Principal | 0 | 0 | 0 | 8,732 | Withhold |
| Calvert | 0 | 0 | 0 | 6,900 | Withhold |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Vincent Milano
ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Vincent Milano”): 42,267,754 for, 3,052,887 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 10,857,249 for, 63,237 withheld, 10,911 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,882,172 | 0 | 0 | 0 | For |
| BlackRock | 2,706,426 | 0 | 0 | 0 | For |
| Fidelity | 2,114,216 | 0 | 0 | 0 | For |
| Charles Schwab | 419,704 | 0 | 0 | 0 | For |
| Equitable | 125,873 | 0 | 0 | 60,400 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 115,378 | 0 | 0 | 0 | For |
| TIAA | 97,857 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,200 | 0 | 0 | 0 | For |
| Pacific Life | 48,081 | 0 | 0 | 0 | For |
| T. Rowe Price | 47,442 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 34,229 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,304 | 0 | 0 | 0 | For |
| State Street | 24,620 | 0 | 0 | 0 | For |
| Nationwide | 21,071 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 16,300 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 16,142 | 0 | 0 | 0 | For |
| ProShares | 15,939 | 0 | 0 | 0 | For |
| SEI | 15,900 | 0 | 0 | 0 | For |
| John Hancock | 14,788 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 12,653 | 0 | 0 | 0 | For |
| DWS | 10,759 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 8,881 | 0 | Abstain |
| Principal | 8,732 | 0 | 0 | 0 | For |
| Calvert | 6,900 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
64% Approved · of votes cast
Prior year: 97.9% for (June 1, 2023 meeting) ▼ 33.9 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this proxy card.
ACLARIS THERAPEUTICS INC.’s own tally for this item (“2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement”): 29,025,583 for, 16,273,816 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,882,172 | 0 | 0 | 0 | For |
| BlackRock | 0 | 2,706,426 | 0 | 0 | Against |
| Fidelity | 625,766 | 1,488,450 | 0 | 0 | Mixed |
| Charles Schwab | 0 | 419,704 | 0 | 0 | Against |
| Equitable | 0 | 186,273 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 115,378 | 0 | 0 | Against |
| TIAA | 0 | 97,857 | 0 | 0 | Against |
| Lincoln Financial | 57,200 | 0 | 0 | 0 | For |
| Pacific Life | 25,112 | 22,969 | 0 | 0 | Mixed |
| T. Rowe Price | 0 | 47,442 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 34,229 | 0 | 0 | Against |
| Harbor ETF Trust | 30,304 | 0 | 0 | 0 | For |
| State Street | 24,620 | 0 | 0 | 0 | For |
| Nationwide | 0 | 21,071 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 16,300 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 0 | 16,142 | 0 | 0 | Against |
| ProShares | 0 | 15,939 | 0 | 0 | Against |
| SEI | 0 | 15,900 | 0 | 0 | Against |
| John Hancock | 0 | 14,788 | 0 | 0 | Against |
| Bridge Builder Trust | 0 | 12,653 | 0 | 0 | Against |
| DWS | 0 | 10,759 | 0 | 0 | Against |
| Jackson National | 0 | 8,881 | 0 | 0 | Against |
| Principal | 0 | 8,732 | 0 | 0 | Against |
| Calvert | 0 | 6,900 | 0 | 0 | Against |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
Fund voting reports, all 34 managers: 5,652,947 for, 5,275,613 against, 2,837 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | 0 | 0 | 0 | For |
| DE Shaw | 0 | 2,857,900 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 2,753,495 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 1,726,873 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 1,565,250 | 0 | 0 | Against |
| BlackRock | 13,929 | 1,449,460 | 0 | 0 | Against |
| State Street | 1,132,475 | 16,861 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 700,735 | 0 | 0 | Against |
| Samsara BioCapital, LLC | 696,171 | 0 | 0 | 0 | For |
| Fidelity | 667,037 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 641,643 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 569,832 | 0 | 0 | 0 | For |
| Northern Trust | 541,822 | 3,742 | 0 | 0 | For |
| Charles Schwab | 0 | 419,704 | 0 | 0 | Against |
| Citadel | 393,993 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 345,256 | 0 | 0 | Against |
| HighTower Advisors, LLC | 0 | 300,990 | 0 | 0 | Against |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 270,000 | 0 | 0 | Against |
| STRS OHIO | 0 | 264,700 | 0 | 0 | Against |
| Aisling Capital Management LP | 196,513 | 0 | 0 | 0 | For |
| AQR | 0 | 182,931 | 0 | 0 | Against |
| BBR PARTNERS, LLC | 180,000 | 0 | 0 | 0 | For |
| Vanguard | 129,049 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 109,767 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 107,345 | 0 | 0 | Against |
Institutional-manager reports, all 80 managers: 10,999,078 for, 10,949,394 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 100.0% for (June 1, 2023 meeting) ▼ 2.0 pts
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2024.
ACLARIS THERAPEUTICS INC.’s own tally for this item (“3. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024”): 56,610,643 for, 1,154,624 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 : The stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 34 asset managers below reported 10,928,560 for, 2,837 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,882,172 | 0 | 0 | 0 | For |
| BlackRock | 2,706,426 | 0 | 0 | 0 | For |
| Fidelity | 2,114,216 | 0 | 0 | 0 | For |
| Charles Schwab | 419,704 | 0 | 0 | 0 | For |
| Equitable | 186,273 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 115,378 | 0 | 0 | 0 | For |
| TIAA | 97,857 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,200 | 0 | 0 | 0 | For |
| Pacific Life | 48,081 | 0 | 0 | 0 | For |
| T. Rowe Price | 47,442 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 34,229 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,304 | 0 | 0 | 0 | For |
| State Street | 24,620 | 0 | 0 | 0 | For |
| Nationwide | 21,071 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 16,300 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 16,142 | 0 | 0 | 0 | For |
| ProShares | 15,939 | 0 | 0 | 0 | For |
| SEI | 15,900 | 0 | 0 | 0 | For |
| John Hancock | 14,788 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 12,653 | 0 | 0 | 0 | For |
| DWS | 10,759 | 0 | 0 | 0 | For |
| Jackson National | 8,881 | 0 | 0 | 0 | For |
| Principal | 8,732 | 0 | 0 | 0 | For |
| Calvert | 6,900 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 4,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,264,786 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 6.85% |
| 2 | BlackRock | 3.80% |
| 3 | Fidelity | 2.97% |
| 4 | Charles Schwab | 0.59% |
| 5 | Equitable | 0.26% |
| 6 | QUANTITATIVE MASTER SERIES LLC | 0.16% |
| 7 | TIAA | 0.14% |
| 8 | Lincoln Financial | 0.08% |
| 9 | Pacific Life | 0.07% |
| 10 | T. Rowe Price | 0.07% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 4.21% |
| 2 | DE Shaw | 4.01% |
| 3 | Rock Springs Capital Management LP | 3.86% |
| 4 | Two Sigma | 2.42% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.20% |
| 6 | BlackRock | 2.05% |
| 7 | State Street | 1.61% |
| 8 | ACADIAN ASSET MANAGEMENT LLC | 0.98% |
| 9 | Samsara BioCapital, LLC | 0.98% |
| 10 | Fidelity | 0.94% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 7,955,160 | 11.16% | Schedule 13G, filed November 21, 2024 |
| Vanguard Group | 6,515,458 | 9.14% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 5,691,352 | 7.99% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 4,077,246 | 5.72% | Form 13F, quarter ended March 31, 2024 |
| D.E. Shaw | 3,282,982 | 4.61% | Form 13F, quarter ended March 31, 2024 |
| Millennium Management | 3,273,492 | 4.59% | Form 13F, quarter ended March 31, 2024 |
| Renaissance Technologies | 1,673,400 | 2.35% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 1,565,054 | 2.20% | Form 13F, quarter ended March 31, 2024 |
| State Street | 1,338,439 | 1.88% | Form 13F, quarter ended March 31, 2024 |
| Two Sigma | 1,329,616 | 1.87% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 71,264,786 shares outstanding, as reported by ACLARIS THERAPEUTICS INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ACLARIS THERAPEUTICS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 106 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 510 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — ACLARIS THERAPEUTICS INC.'s filing reports the proposal as approved, with 64% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ACLARIS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ACLARIS THERAPEUTICS INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ACLARIS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “ACLARIS THERAPEUTICS (ACRS) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/aclaris-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.